Companies: 49,246 Total Market Cap: 132441797263938.02

Addex Therapeutics Ltd

NASDAQ: ADXN
Healthcare Biotechnology
Rank #41589
Market Cap 7.02 M
Volume 0
Price 8.37
Change (%) 1.53%
Country or region Switzerland Switzerland

Addex Therapeutics Ltd's latest marketcap:

7.02 M

As of 05/20/2025, Addex Therapeutics Ltd's market capitalization has reached $7.02 M. According to our data, Addex Therapeutics Ltd is the 41589th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 7.02 M
Revenue (ttm) 452,495
Net Income (ttm) 7.79 M
Shares Out 109.07 M
EPS (ttm) 0.08
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 06/05/2025
Market Cap Chart
Data Updated: 05/20/2025

Addex Therapeutics Ltd's yearly market capitalization.

Addex Therapeutics Ltd has seen its market value drop from $53.24 M to $7.02 M since 2020, representing a total decrease of 86.82% and an annual compound decline rate (CAGR) of 36.99%.
Date Market Cap Change (%)
05/20/2025 $7.02 M 4.55%
12/30/2024 $5.62 M -9.01%
12/29/2023 $6.18 M -40.48%
12/30/2022 $10.39 M -73.65%
12/30/2021 $39.42 M -25.96%
12/30/2020 $53.24 M

Company Profile

About Addex Therapeutics Ltd

Addex Therapeutics Ltd is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics for central nervous system (CNS) disorders. The company focuses on innovative treatments targeting G-protein coupled receptors and enzymes.

Key Programs & Research

  • Dipraglurant – A treatment for Parkinson’s disease levodopa-induced dyskinesia, dystonia, and post-stroke/TBI recovery.
  • ADX71149 – An orally active mGlu2 PAM (metabotropic glutamate receptor subtype 2 positive allosteric modulator) for epilepsy.
  • GABAB PAM – Investigated for pain, anxiety, overactive bladder, addiction, and substance use disorder.

Strategic Collaborations

  • Janssen Pharmaceuticals Inc. – Partnership for mGlu2 PAM compounds targeting CNS diseases.
  • Indivior PLC – Research agreement for GABAB PAM compounds in addiction and CNS disorders.
  • The Charcot–Marie–Tooth Association – Evaluating GABAB PAM in preclinical CMT1A models.

Company Background

Founded in 2002 and headquartered in Geneva, Switzerland, the company was previously known as Addex Pharmaceuticals Ltd before rebranding to Addex Therapeutics Ltd.

Frequently Asked Questions

As of 05/20/2025, Addex Therapeutics Ltd (including the parent company, if applicable) has an estimated market capitalization of $7.02 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Addex Therapeutics Ltd global market capitalization ranking is approximately 41589 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Switzerland
Founded 2002
IPO Date n/a
Employees 23
CEO Timothy Dyer
Sector Healthcare
Industry Biotechnology
Address Chemin des Mines, 9
Geneva, 1202
Switzerland
Website https://www.addextherapeutics.com
People Also Watch
VRTX
444.31 1.53%
CSL Limited
156.27 1.53%
REGN
605.54 1.53%
KRX-207940
731.22 1.53%